Literature DB >> 29319691

Drugmakers cling to dual IL-13/IL-4 blockbuster hopes.

Cormac Sheridan.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29319691     DOI： 10.1038/nbt0118-3

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  5 in total

1.  Lebrikizumab treatment in adults with asthma.

Authors:  Jonathan Corren; Robert F Lemanske; Nicola A Hanania; Phillip E Korenblat; Merdad V Parsey; Joseph R Arron; Jeffrey M Harris; Heleen Scheerens; Lawren C Wu; Zheng Su; Sofia Mosesova; Mark D Eisner; Sean P Bohen; John G Matthews
Journal:  N Engl J Med       Date:  2011-08-03       Impact factor: 91.245

2.  First eczema biologic debuts but price could restrict use.

Authors:  Elie Dolgin
Journal:  Nat Biotechnol       Date:  2017-05-09       Impact factor: 54.908

Review 3.  Targeting key proximal drivers of type 2 inflammation in disease.

Authors:  Namita A Gandhi; Brandy L Bennett; Neil M H Graham; Gianluca Pirozzi; Neil Stahl; George D Yancopoulos
Journal:  Nat Rev Drug Discov       Date:  2015-10-16       Impact factor: 84.694

4.  Tezepelumab in Adults with Uncontrolled Asthma.

Authors:  Jonathan Corren; Jane R Parnes; Liangwei Wang; May Mo; Stephanie L Roseti; Janet M Griffiths; René van der Merwe
Journal:  N Engl J Med       Date:  2017-09-07       Impact factor: 91.245

Review 5.  Allergy and allergic diseases. First of two parts.

Authors:  A B Kay
Journal:  N Engl J Med       Date:  2001-01-04       Impact factor: 91.245
  5 in total
  4 in total

1.  Fra-2-expressing macrophages promote lung fibrosis in mice.

Authors:  Alvaro C Ucero; Latifa Bakiri; Ben Roediger; Masakatsu Suzuki; Maria Jimenez; Pratyusha Mandal; Paola Braghetta; Paolo Bonaldo; Luis Paz-Ares; Coral Fustero-Torre; Pilar Ximenez-Embun; Ana Isabel Hernandez; Diego Megias; Erwin F Wagner
Journal:  J Clin Invest       Date:  2019-05-28       Impact factor: 14.808

2.  Combination of TLR agonist and miR146a mimics attenuates ovalbumin-induced asthma.

Authors:  Xinhua Wang; Xiaoxian Lu; Chenhui Ma; Lihong Ma; Shuguang Han
Journal:  Mol Med       Date:  2020-06-29       Impact factor: 6.354

3.  Engineering of anti-human interleukin-4 receptor alpha antibodies with potent antagonistic activity.

Authors:  Jung-Eun Kim; Keunok Jung; Jeong-Ah Kim; Seung-Hyun Kim; Hae-Sim Park; Yong-Sung Kim
Journal:  Sci Rep       Date:  2019-05-23       Impact factor: 4.379

Review 4.  IL-4 and IL-13 Receptor Signaling From 4PS to Insulin Receptor Substrate 2: There and Back Again, a Historical View.

Authors:  Achsah D Keegan; Jose Zamorano; Aleksander Keselman; Nicola M Heller
Journal:  Front Immunol       Date:  2018-05-15       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.